Sox2‐dependent inhibition of p21 is associated with poor prognosis of endometrial cancer
Sex‐determining region Y‐box 2 (SOX2) is an essential factor involved in the self‐renewal and pluripotency of embryonic stem cells and has functions in cell survival and progression in many types of cancers. Here, we found that several endometrial cancer cell lines expressed SOX2, which was required...
Gespeichert in:
| Veröffentlicht in: | Cancer science 2017-04, Vol.108 (4), p.632-640 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 640 |
|---|---|
| container_issue | 4 |
| container_start_page | 632 |
| container_title | Cancer science |
| container_volume | 108 |
| creator | Yamawaki, Kaoru Ishiguro, Tatsuya Mori, Yutaro Yoshihara, Kosuke Suda, Kazuaki Tamura, Ryo Yamaguchi, Masayuki Sekine, Masayuki Kashima, Katsunori Higuchi, Masaya Fujii, Masahiro Okamoto, Koji Enomoto, Takayuki |
| description | Sex‐determining region Y‐box 2 (SOX2) is an essential factor involved in the self‐renewal and pluripotency of embryonic stem cells and has functions in cell survival and progression in many types of cancers. Here, we found that several endometrial cancer cell lines expressed SOX2, which was required for cell growth. Additionally, SOX2 overexpression regulated the expression of cyclin‐dependent kinase inhibitor 1A (CDKN1A), and SOX2 specifically bound to p21 promoter DNA in endometrial cancer cell lines expressing SOX2. Expressions of SOX2 in endometrial cancer patients were significantly correlated with histological grade and poor prognosis. Moreover, low p21 together with high SOX2 expressions in advanced endometrial cancer patients were associated with the most unfavorable outcomes of patients. These results indicated that simultaneous measurement of SOX2 and p21 expression in endometrial cancer patients may be a useful biomarker for patient prognosis.
SOX2 is required for endometrial cancer cell growth. Expressions of SOX2 in endometrial cancer patients is significantly correlated with histological grade and poor prognosis. Low p21 together with high SOX2 expressions in advanced endometrial cancer patients are associated with the most unfavorable outcomes of patients. |
| doi_str_mv | 10.1111/cas.13196 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5406528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1867540037</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5566-c9c189495eab4e1b789f3bd4a5a48d6c41f00191add4c757276b030fdcf1b7bc3</originalsourceid><addsrcrecordid>eNqNkbtKBDEUhoMo3gtfQFJqMZpMMrk0gizeQLBQG5uQSTJuZHYyJrOudj6Cz-iTGF0VLQTTnMD5zsc5_ABsYbSH89s3Ou1hgiVbAKuYUFlwhNjix58XEpFyBayldIcQYVTSZbBSCiwEE9UquLkMj-Xr84t1veus6wbou7Gv_eBDB0MD-xJDn6BOKRivB2fhzA9j2IcQYR_DbRdSbmcwT4eJG6LXLTS6My5ugKVGt8ltftZ1cH18dDU6Lc4vTs5Gh-eFqSrGCiMNFpLKyumaOlxzIRtSW6orTYVlhuIGISyxtpYaXvGSsxoR1FjTZLg2ZB0czL39tJ44a_IRUbeqj36i45MK2qvfnc6P1W14UBVFrCpFFux8CmK4n7o0qIlPxrWt7lyYJpXX40QgIuQ_UMazFhGe0d05amJIKbrmeyOM1HtsKsemPmLL7PbPE77Jr5wysD8HZr51T3-b1Ojwcq58AxgUpBI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1867540037</pqid></control><display><type>article</type><title>Sox2‐dependent inhibition of p21 is associated with poor prognosis of endometrial cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Yamawaki, Kaoru ; Ishiguro, Tatsuya ; Mori, Yutaro ; Yoshihara, Kosuke ; Suda, Kazuaki ; Tamura, Ryo ; Yamaguchi, Masayuki ; Sekine, Masayuki ; Kashima, Katsunori ; Higuchi, Masaya ; Fujii, Masahiro ; Okamoto, Koji ; Enomoto, Takayuki</creator><creatorcontrib>Yamawaki, Kaoru ; Ishiguro, Tatsuya ; Mori, Yutaro ; Yoshihara, Kosuke ; Suda, Kazuaki ; Tamura, Ryo ; Yamaguchi, Masayuki ; Sekine, Masayuki ; Kashima, Katsunori ; Higuchi, Masaya ; Fujii, Masahiro ; Okamoto, Koji ; Enomoto, Takayuki</creatorcontrib><description>Sex‐determining region Y‐box 2 (SOX2) is an essential factor involved in the self‐renewal and pluripotency of embryonic stem cells and has functions in cell survival and progression in many types of cancers. Here, we found that several endometrial cancer cell lines expressed SOX2, which was required for cell growth. Additionally, SOX2 overexpression regulated the expression of cyclin‐dependent kinase inhibitor 1A (CDKN1A), and SOX2 specifically bound to p21 promoter DNA in endometrial cancer cell lines expressing SOX2. Expressions of SOX2 in endometrial cancer patients were significantly correlated with histological grade and poor prognosis. Moreover, low p21 together with high SOX2 expressions in advanced endometrial cancer patients were associated with the most unfavorable outcomes of patients. These results indicated that simultaneous measurement of SOX2 and p21 expression in endometrial cancer patients may be a useful biomarker for patient prognosis.
SOX2 is required for endometrial cancer cell growth. Expressions of SOX2 in endometrial cancer patients is significantly correlated with histological grade and poor prognosis. Low p21 together with high SOX2 expressions in advanced endometrial cancer patients are associated with the most unfavorable outcomes of patients.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.13196</identifier><identifier>PMID: 28188685</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Animals ; Biomarker ; Blotting, Western ; cell cycle ; Cell Line, Tumor ; Cyclin-Dependent Kinase Inhibitor p21 - genetics ; Cyclin-Dependent Kinase Inhibitor p21 - metabolism ; endometrial cancer ; Endometrial Neoplasms - diagnosis ; Endometrial Neoplasms - genetics ; Endometrial Neoplasms - metabolism ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Mice, Inbred NOD ; Mice, Knockout ; Mice, SCID ; Middle Aged ; Original ; p21 ; Prognosis ; Reverse Transcriptase Polymerase Chain Reaction ; RNA Interference ; sex‐determining region Y‐box 2 ; SOXB1 Transcription Factors - genetics ; SOXB1 Transcription Factors - metabolism ; Transplantation, Heterologous ; Tumor Suppressor Protein p53 - genetics ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>Cancer science, 2017-04, Vol.108 (4), p.632-640</ispartof><rights>2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5566-c9c189495eab4e1b789f3bd4a5a48d6c41f00191add4c757276b030fdcf1b7bc3</citedby><cites>FETCH-LOGICAL-c5566-c9c189495eab4e1b789f3bd4a5a48d6c41f00191add4c757276b030fdcf1b7bc3</cites><orcidid>0000-0002-6445-4066</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406528/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406528/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1416,11561,27923,27924,45573,45574,46051,46475,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28188685$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamawaki, Kaoru</creatorcontrib><creatorcontrib>Ishiguro, Tatsuya</creatorcontrib><creatorcontrib>Mori, Yutaro</creatorcontrib><creatorcontrib>Yoshihara, Kosuke</creatorcontrib><creatorcontrib>Suda, Kazuaki</creatorcontrib><creatorcontrib>Tamura, Ryo</creatorcontrib><creatorcontrib>Yamaguchi, Masayuki</creatorcontrib><creatorcontrib>Sekine, Masayuki</creatorcontrib><creatorcontrib>Kashima, Katsunori</creatorcontrib><creatorcontrib>Higuchi, Masaya</creatorcontrib><creatorcontrib>Fujii, Masahiro</creatorcontrib><creatorcontrib>Okamoto, Koji</creatorcontrib><creatorcontrib>Enomoto, Takayuki</creatorcontrib><title>Sox2‐dependent inhibition of p21 is associated with poor prognosis of endometrial cancer</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>Sex‐determining region Y‐box 2 (SOX2) is an essential factor involved in the self‐renewal and pluripotency of embryonic stem cells and has functions in cell survival and progression in many types of cancers. Here, we found that several endometrial cancer cell lines expressed SOX2, which was required for cell growth. Additionally, SOX2 overexpression regulated the expression of cyclin‐dependent kinase inhibitor 1A (CDKN1A), and SOX2 specifically bound to p21 promoter DNA in endometrial cancer cell lines expressing SOX2. Expressions of SOX2 in endometrial cancer patients were significantly correlated with histological grade and poor prognosis. Moreover, low p21 together with high SOX2 expressions in advanced endometrial cancer patients were associated with the most unfavorable outcomes of patients. These results indicated that simultaneous measurement of SOX2 and p21 expression in endometrial cancer patients may be a useful biomarker for patient prognosis.
SOX2 is required for endometrial cancer cell growth. Expressions of SOX2 in endometrial cancer patients is significantly correlated with histological grade and poor prognosis. Low p21 together with high SOX2 expressions in advanced endometrial cancer patients are associated with the most unfavorable outcomes of patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Animals</subject><subject>Biomarker</subject><subject>Blotting, Western</subject><subject>cell cycle</subject><subject>Cell Line, Tumor</subject><subject>Cyclin-Dependent Kinase Inhibitor p21 - genetics</subject><subject>Cyclin-Dependent Kinase Inhibitor p21 - metabolism</subject><subject>endometrial cancer</subject><subject>Endometrial Neoplasms - diagnosis</subject><subject>Endometrial Neoplasms - genetics</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kaplan-Meier Estimate</subject><subject>Mice, Inbred NOD</subject><subject>Mice, Knockout</subject><subject>Mice, SCID</subject><subject>Middle Aged</subject><subject>Original</subject><subject>p21</subject><subject>Prognosis</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA Interference</subject><subject>sex‐determining region Y‐box 2</subject><subject>SOXB1 Transcription Factors - genetics</subject><subject>SOXB1 Transcription Factors - metabolism</subject><subject>Transplantation, Heterologous</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNqNkbtKBDEUhoMo3gtfQFJqMZpMMrk0gizeQLBQG5uQSTJuZHYyJrOudj6Cz-iTGF0VLQTTnMD5zsc5_ABsYbSH89s3Ou1hgiVbAKuYUFlwhNjix58XEpFyBayldIcQYVTSZbBSCiwEE9UquLkMj-Xr84t1veus6wbou7Gv_eBDB0MD-xJDn6BOKRivB2fhzA9j2IcQYR_DbRdSbmcwT4eJG6LXLTS6My5ugKVGt8ltftZ1cH18dDU6Lc4vTs5Gh-eFqSrGCiMNFpLKyumaOlxzIRtSW6orTYVlhuIGISyxtpYaXvGSsxoR1FjTZLg2ZB0czL39tJ44a_IRUbeqj36i45MK2qvfnc6P1W14UBVFrCpFFux8CmK4n7o0qIlPxrWt7lyYJpXX40QgIuQ_UMazFhGe0d05amJIKbrmeyOM1HtsKsemPmLL7PbPE77Jr5wysD8HZr51T3-b1Ojwcq58AxgUpBI</recordid><startdate>201704</startdate><enddate>201704</enddate><creator>Yamawaki, Kaoru</creator><creator>Ishiguro, Tatsuya</creator><creator>Mori, Yutaro</creator><creator>Yoshihara, Kosuke</creator><creator>Suda, Kazuaki</creator><creator>Tamura, Ryo</creator><creator>Yamaguchi, Masayuki</creator><creator>Sekine, Masayuki</creator><creator>Kashima, Katsunori</creator><creator>Higuchi, Masaya</creator><creator>Fujii, Masahiro</creator><creator>Okamoto, Koji</creator><creator>Enomoto, Takayuki</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TO</scope><scope>H94</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6445-4066</orcidid></search><sort><creationdate>201704</creationdate><title>Sox2‐dependent inhibition of p21 is associated with poor prognosis of endometrial cancer</title><author>Yamawaki, Kaoru ; Ishiguro, Tatsuya ; Mori, Yutaro ; Yoshihara, Kosuke ; Suda, Kazuaki ; Tamura, Ryo ; Yamaguchi, Masayuki ; Sekine, Masayuki ; Kashima, Katsunori ; Higuchi, Masaya ; Fujii, Masahiro ; Okamoto, Koji ; Enomoto, Takayuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5566-c9c189495eab4e1b789f3bd4a5a48d6c41f00191add4c757276b030fdcf1b7bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Animals</topic><topic>Biomarker</topic><topic>Blotting, Western</topic><topic>cell cycle</topic><topic>Cell Line, Tumor</topic><topic>Cyclin-Dependent Kinase Inhibitor p21 - genetics</topic><topic>Cyclin-Dependent Kinase Inhibitor p21 - metabolism</topic><topic>endometrial cancer</topic><topic>Endometrial Neoplasms - diagnosis</topic><topic>Endometrial Neoplasms - genetics</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kaplan-Meier Estimate</topic><topic>Mice, Inbred NOD</topic><topic>Mice, Knockout</topic><topic>Mice, SCID</topic><topic>Middle Aged</topic><topic>Original</topic><topic>p21</topic><topic>Prognosis</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA Interference</topic><topic>sex‐determining region Y‐box 2</topic><topic>SOXB1 Transcription Factors - genetics</topic><topic>SOXB1 Transcription Factors - metabolism</topic><topic>Transplantation, Heterologous</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamawaki, Kaoru</creatorcontrib><creatorcontrib>Ishiguro, Tatsuya</creatorcontrib><creatorcontrib>Mori, Yutaro</creatorcontrib><creatorcontrib>Yoshihara, Kosuke</creatorcontrib><creatorcontrib>Suda, Kazuaki</creatorcontrib><creatorcontrib>Tamura, Ryo</creatorcontrib><creatorcontrib>Yamaguchi, Masayuki</creatorcontrib><creatorcontrib>Sekine, Masayuki</creatorcontrib><creatorcontrib>Kashima, Katsunori</creatorcontrib><creatorcontrib>Higuchi, Masaya</creatorcontrib><creatorcontrib>Fujii, Masahiro</creatorcontrib><creatorcontrib>Okamoto, Koji</creatorcontrib><creatorcontrib>Enomoto, Takayuki</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamawaki, Kaoru</au><au>Ishiguro, Tatsuya</au><au>Mori, Yutaro</au><au>Yoshihara, Kosuke</au><au>Suda, Kazuaki</au><au>Tamura, Ryo</au><au>Yamaguchi, Masayuki</au><au>Sekine, Masayuki</au><au>Kashima, Katsunori</au><au>Higuchi, Masaya</au><au>Fujii, Masahiro</au><au>Okamoto, Koji</au><au>Enomoto, Takayuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sox2‐dependent inhibition of p21 is associated with poor prognosis of endometrial cancer</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2017-04</date><risdate>2017</risdate><volume>108</volume><issue>4</issue><spage>632</spage><epage>640</epage><pages>632-640</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>Sex‐determining region Y‐box 2 (SOX2) is an essential factor involved in the self‐renewal and pluripotency of embryonic stem cells and has functions in cell survival and progression in many types of cancers. Here, we found that several endometrial cancer cell lines expressed SOX2, which was required for cell growth. Additionally, SOX2 overexpression regulated the expression of cyclin‐dependent kinase inhibitor 1A (CDKN1A), and SOX2 specifically bound to p21 promoter DNA in endometrial cancer cell lines expressing SOX2. Expressions of SOX2 in endometrial cancer patients were significantly correlated with histological grade and poor prognosis. Moreover, low p21 together with high SOX2 expressions in advanced endometrial cancer patients were associated with the most unfavorable outcomes of patients. These results indicated that simultaneous measurement of SOX2 and p21 expression in endometrial cancer patients may be a useful biomarker for patient prognosis.
SOX2 is required for endometrial cancer cell growth. Expressions of SOX2 in endometrial cancer patients is significantly correlated with histological grade and poor prognosis. Low p21 together with high SOX2 expressions in advanced endometrial cancer patients are associated with the most unfavorable outcomes of patients.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>28188685</pmid><doi>10.1111/cas.13196</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6445-4066</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2017-04, Vol.108 (4), p.632-640 |
| issn | 1347-9032 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5406528 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wiley-Blackwell Open Access Titles; Wiley Online Library All Journals; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Animals Biomarker Blotting, Western cell cycle Cell Line, Tumor Cyclin-Dependent Kinase Inhibitor p21 - genetics Cyclin-Dependent Kinase Inhibitor p21 - metabolism endometrial cancer Endometrial Neoplasms - diagnosis Endometrial Neoplasms - genetics Endometrial Neoplasms - metabolism Female Gene Expression Regulation, Neoplastic Humans Immunohistochemistry Kaplan-Meier Estimate Mice, Inbred NOD Mice, Knockout Mice, SCID Middle Aged Original p21 Prognosis Reverse Transcriptase Polymerase Chain Reaction RNA Interference sex‐determining region Y‐box 2 SOXB1 Transcription Factors - genetics SOXB1 Transcription Factors - metabolism Transplantation, Heterologous Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism |
| title | Sox2‐dependent inhibition of p21 is associated with poor prognosis of endometrial cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T17%3A28%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sox2%E2%80%90dependent%20inhibition%20of%20p21%20is%20associated%20with%20poor%20prognosis%20of%20endometrial%20cancer&rft.jtitle=Cancer%20science&rft.au=Yamawaki,%20Kaoru&rft.date=2017-04&rft.volume=108&rft.issue=4&rft.spage=632&rft.epage=640&rft.pages=632-640&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.13196&rft_dat=%3Cproquest_pubme%3E1867540037%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1867540037&rft_id=info:pmid/28188685&rfr_iscdi=true |